Supplementary Figures S1-S10 from Clonal Hematopoiesis of Indeterminate Potential Influences Breast Cancer Outcomes in a Genotype-Specific Manner

Le résumé fourni par la source

Supplemental Figure S1. DMFS in the retrospective patient cohort study. Supplemental Figure S2. Breast tumor weight (g) at endpoint of Dnmt3a-CHIP and Tet2-CHIP, with differences compared to littermate controls evaluated via t test. Supplemental Figure S3. H&E staining and IHC for CD4, CD8, and F4/80 on FFPE tumors from Tet2-CHIP and control mice. Supplemental Figure S4. H&E staining and IHC for CD4, CD8, and F4/80 on FFPE tumors from Dnmt3a-CHIP and control mice. Supplemental Figure S5. Schematic describing how cells were analyzed for Figure 3D and Supplemental Figure S8. Supplemental Figure S6. Subclusters of non-T cell (myeloid, B cell, and NK cell), CD8 T cell, and CD4 T cell populations detected via CyTOF in the Tet2-CHIP model. Supplemental Figure S7. Subclusters of non-T cell (myeloid, B cell, and NK cell), CD8 T cell, and CD4 T cell populations detected via CyTOF in the Dnmt3a-CHIP model. Supplemental Figure S8. A, Tet2-CHIP model and B, Dnmt3a-CHIP model subcluster abundances, measured as percent of parent general immune subset (indicated by y-axis; “myeloid” = non-T cell), observed in peripheral blood (PB) and tumor immune infiltrate (T). Supplemental Figure S9. Schematic describing how cells were analyzed for Figures 3E and 3F and Supplemental Figure S10. Supplemental Figure S10. CD45.2+ burden among immune cell subclusters in the Tet2-CHIP (A) and Dnmt3a-CHIP (B) mouse models, measured in peripheral blood (PB) and tumor immune infiltrate.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.